Combination therapies and uses for treating cancer
AssigneePfizer Inc.
InventorsStephen George DANN, Koleen Jill EISELE, Conglin FAN, Manfred KRAUS, Pei-Pei KUNG, Shikhar SHARMA, Hui WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the treatment of cancer and/or cancer-associated disease. Certain aspects relate to the treatment of an individual having cancer or cancer-associated disease by administering to the individual a combination therapy of a first therapeutic agent that is an EZH2 inhibitor, a second therapeutic agent that is a CDK inhibitor, and a third therapeutic agent that is a selective estrogen receptor degrader.
Claims19
A method of treating a cancer in a subject comprising administering to the subject a combination therapy which comprises a therapeutically effective amount of a first therapeutic agent that is an EZH2 inhibitor or a pharmaceutically acceptable salt thereof;
- a therapeutically effective amount of a second therapeutic agent that is a CDK inhibitor or a pharmaceutically acceptable salt thereof;
- and a therapeutically effective amount of a third therapeutic agent that is fulvestrant or a pharmaceutically acceptable salt thereof.
A combination therapy, wherein the combination therapy comprises an EZH2 inhibitor that is CPI-1205, GSK126, valemetostat, tazemetostat, PF-06821497, GSK-2816126, 3-deazaneplanocin A, or a pharmaceutically acceptable salt thereof;
- a CDK inhibitor that is palbociclib or a pharmaceutically acceptable salt thereof, or PF-06873600 or a pharmaceutically acceptable salt thereof;
- and fulvestrant or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.